Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Neil Stuart Horowitz, M.D.


This page shows the publications co-authored by Neil Horowitz and Michael Worley.
Connection Strength

  1. Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
    View in: PubMed
    Score: 0.635
  2. Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
    View in: PubMed
    Score: 0.586
  3. Kanbergs AN, Manning-Geist BL, Pelletier A, Sullivan MW, Del Carmen MG, Horowitz NS, Growdon WB, Clark RM, Muto MG, Worley MJ. Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020 Sep 18.
    View in: PubMed
    Score: 0.249
  4. Li S, Manning-Geist B, Gockley A, Ramos A, Sisodia RC, Del Carmen M, Growdon WB, Horowitz N, Berkowitz R, Worley M. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 Jul; 30(7):1052-1057.
    View in: PubMed
    Score: 0.243
  5. Gonzalez R, Gockley AA, Melamed A, Sugrue R, Clark RM, Del Carmen MG, Growdon W, Berkowitz RS, Horowitz NS, Worley MJ. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020 Jun; 157(3):700-705.
    View in: PubMed
    Score: 0.240
  6. Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
    View in: PubMed
    Score: 0.226
  7. Gockley AA, Fiascone S, Hicks Courant K, Pepin K, Del Carmen M, Clark RM, Goldberg J, Horowitz N, Berkowitz R, Worley M. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
    View in: PubMed
    Score: 0.223
  8. Manning-Geist BL, Alimena S, Del Carmen MG, Goodman A, Clark RM, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ. Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
    View in: PubMed
    Score: 0.221
  9. Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
    View in: PubMed
    Score: 0.213
  10. Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
    View in: PubMed
    Score: 0.205
  11. Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
    View in: PubMed
    Score: 0.162
  12. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.054
  13. Davis M, Strickland K, Easter SR, Worley M, Feltmate C, Muto M, Horowitz N, Berkowitz R, Feldman S. The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
    View in: PubMed
    Score: 0.053
  14. Davis M, Aviki E, Rauh-Hain JA, Worley M, Berkowitz R, Schorge J, Muto M, Clark Sisodia R, Horowitz N, Del Carmen M. Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
    View in: PubMed
    Score: 0.046
  15. Melamed A, Katz Eriksen JL, Hinchcliff EM, Worley MJ, Berkowitz RS, Horowitz NS, Muto MG, Urman RD, Feltmate CM. Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.